{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T08:21:12Z","timestamp":1761639672709,"version":"build-2065373602"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007912","name":"Australian Government Department of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bmcl.2025.130405","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T23:47:04Z","timestamp":1758152824000},"page":"130405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The Pyrimidinyl Hydrazones: Selective for anti-Cancer cytotoxicity"],"prefix":"10.1016","volume":"130","author":[{"given":"Rohina","family":"Alim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Andrew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Parkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bmcl.2025.130405_bb0010","first-page":"514","article-title":"Cancer immunotherapy, part 3: challenges and future trends","volume":"42","author":"Ventola","year":"2017","journal-title":"P T"},{"author":"National Cancer Institute","key":"10.1016\/j.bmcl.2025.130405_bb0015"},{"key":"10.1016\/j.bmcl.2025.130405_bb0020","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1089\/ars.2012.4540","article-title":"Novel chelators for cancer treatment: where are we now?","volume":"18","author":"Merlot","year":"2013","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.bmcl.2025.130405_bb0025","doi-asserted-by":"crossref","first-page":"14901","DOI":"10.1073\/pnas.0604979103","article-title":"A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics","volume":"103","author":"Whitnall","year":"2006","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130405_bb0030","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/pr.57.4.2","article-title":"The evolution of iron chelators for the treatment of iron overload disease and cancer","volume":"57","author":"Kalinowski","year":"2005","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bmcl.2025.130405_bb0035","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3390\/inorganics6040126","article-title":"Iron and copper intracellular chelation as an anticancer drug strategy","volume":"6","author":"Gaur","year":"2018","journal-title":"Inorganics"},{"key":"10.1016\/j.bmcl.2025.130405_bb0040","doi-asserted-by":"crossref","first-page":"169","DOI":"10.31689\/rmm.2019.26.4.169","article-title":"Trace elements and cancer","volume":"26","author":"Elena","year":"2019","journal-title":"Medicina Moderna - Modern Medicine"},{"key":"10.1016\/j.bmcl.2025.130405_bb0045","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/blood-2004-05-1866","article-title":"Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation","volume":"104","author":"Le","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bmcl.2025.130405_bb0050","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nrc1886","article-title":"Metastasis: a question of life or death","volume":"6","author":"Mehlen","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmcl.2025.130405_bb0055","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/stem.2967","article-title":"Iron homeostasis determines fate of human pluripotent stem cells via glycerophospholipids-epigenetic circuit","volume":"37","author":"Han","year":"2019","journal-title":"Stem Cells"},{"key":"10.1016\/j.bmcl.2025.130405_bb0060","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.freeradbiomed.2018.07.015","article-title":"Dysregulation of iron metabolism in cancer stem cells","volume":"133","author":"Recalcati","year":"2019","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130405_bb0065","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1186\/s12885-016-2744-9","article-title":"Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo","volume":"16","author":"Harima","year":"2016","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130405_bb0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40591-015-0039-1","article-title":"Polymeric nanocarriers for the treatment of systemic iron overload","volume":"3","author":"Hamilton","year":"2015","journal-title":"Mol Cell Ther"},{"issue":"6","key":"10.1016\/j.bmcl.2025.130405_bb0075","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1056\/NEJMc1105726","article-title":"Deferoxamine for advanced hepatocellular carcinoma","volume":"365","author":"Yamasaki","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2025.130405_bb0080","first-page":"166","article-title":"Expanding horizons in iron chelation and the treatment of cancer: role of iron in the regulation of ER stress and the epithelial \u2013 mesenchymal transition","volume":"1845","author":"Lane","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bmcl.2025.130405_bb0085","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.freeradbiomed.2010.10.696","article-title":"A copper chelate of the thiosemicarbazone NSC 689534 induces oxidative \/ ER stress and inhibits tumor growth in vitro and in vivo","volume":"50","author":"Hancock","year":"2011","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.bmcl.2025.130405_bb0090","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1186\/s12967-023-04533-5","article-title":"Elesclomol, a copper-transporting therapeutic agent targeting mitochondria: from discovery to its novel applications","volume":"21","author":"Tarin","year":"2023","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130405_bb0095","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s13046-022-02485-0","article-title":"Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy","volume":"41","author":"Zheng","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.bmcl.2025.130405_bb0100","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1200\/JCO.2012.44.5585","article-title":"Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma","volume":"31","author":"O\u2019Day","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmcl.2025.130405_bb0105","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.2004.07.158","article-title":"Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion","volume":"22","author":"Wadler","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmcl.2025.130405_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/0008-5472.CAN-03-3048","article-title":"In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase","volume":"64","author":"Shao","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2025.130405_bb0115","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1021\/jm970255w","article-title":"Azinyl and diazinyl hydrazones derived from aryl-N hereroaryl ketones: synthesis and antiproliferative activity","volume":"40","author":"Easmon","year":"1997","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130405_bb0120","first-page":"402","article-title":"Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311","volume":"9","author":"Chaston","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmcl.2025.130405_bb0125","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/1535-7163.MCT-05-0384","article-title":"A ferrous\u2013triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase","volume":"5","author":"Shao","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmcl.2025.130405_bb0130","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/0006-2952(81)90386-5","article-title":"Interaction of 2-formylpyridine thiosemicarbazonato copper(II) with Ehrlich ascites tumor cells","volume":"30","author":"Saryan","year":"1981","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmcl.2025.130405_bb0135","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1021\/bi00482a014","article-title":"Oxidative stress induced by a copper\u2013thiosemicarbazone complex","volume":"29","author":"Byrnes","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmcl.2025.130405_bb0140","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1089\/ars.2009.2541","article-title":"Redox-directed cancer therapeutics: molecular mechanisms and opportunities","volume":"11","author":"Wondrak","year":"2009","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.bmcl.2025.130405_bb0145","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ctrv.2008.07.004","article-title":"Elevated copper and oxidative stress in cancer cells as a target for cancer treatment","volume":"35","author":"Gupte","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bmcl.2025.130405_bb0150","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd2803","article-title":"Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?","volume":"8","author":"Trachootham","year":"2009","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.bmcl.2025.130405_bb0155","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1021\/acs.jmedchem.6b00238","article-title":"Zinc(II)\u2013Thiosemicarbazone complexes are localized to the lysosomal compartment where they transmetallate with copper ions to induce cytotoxicity","volume":"59","author":"Stacy","year":"2016","journal-title":"J Med Chem"},{"issue":"15","key":"10.1016\/j.bmcl.2025.130405_bb0160","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1021\/jm100561b","article-title":"Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity","volume":"53","author":"Jansson","year":"2010","journal-title":"J Med Chem"},{"issue":"22","key":"10.1016\/j.bmcl.2025.130405_bb0165","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.1021\/jm0606342","article-title":"Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity","volume":"49","author":"Richardson","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130405_bb0170","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/ejic.200901174","article-title":"Comparative solution equilibrium study of the interactions of copper(II), iron(II) and zinc(II) with Triapine (3-aminopyridine-2-carbaldehyde thiosemicarbazone) and related ligands","volume":"11","author":"Enyedy","year":"2010","journal-title":"Eur J Inorg Chem"},{"key":"10.1016\/j.bmcl.2025.130405_bb0175","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1021\/jm900528d","article-title":"Impact of etal coordination on cytotoxicity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine) and novel insights into terminal dimethylation","volume":"52","author":"Kowol","year":"2009","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.bmcl.2025.130405_bb0180","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1016\/S0021-9258(17)43139-5","article-title":"Iron-catalyzed hydroxyl radical formation","volume":"259","author":"Graf","year":"1984","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2025.130405_bb0185","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/1471-2407-14-527","article-title":"Copper chelation selectively kills colon cancer cells through redox cycling and generation of reactive oxygen species","volume":"14","author":"Fatfat","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bmcl.2025.130405_bb0190","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1383-5742(97)00041-0","article-title":"Adduct formation, mutagenesis and nucleotide excision repair of DNA damage produced by reactive oxygen species and lipid peroxidation product","volume":"410","author":"M\u00f8ller","year":"1998","journal-title":"Mutat Res\/Rev Mutat Res"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130405_bb0195","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.exger.2007.11.005","article-title":"Metallothionein redox biology in the cytoprotective and cytotoxic functions of zinc","volume":"43","author":"Maret","year":"2008","journal-title":"Exp Gerontol"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130405_bb0200","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10534-008-9186-z","article-title":"Molecular aspects of human cellular zinc homeostasis: redox control of zinc potentials and zinc signals","volume":"22","author":"Maret","year":"2009","journal-title":"Biometals"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130405_bb0205","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-016-0330-x","article-title":"The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms","volume":"9","author":"Guo","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bmcl.2025.130405_bb0210","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.bioorg.2019.03.045","article-title":"Synthesis of TPEN variants to improve cancer cells selective killing capacity","volume":"87","author":"Schaefer-Ramadan","year":"2019","journal-title":"Bioorg Chem"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130405_bb0215","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.tibs.2015.11.012","article-title":"Regulators of iron homeostasis: new players in metabolism, cell death, and disease","volume":"41","author":"Bogdan","year":"2016","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.bmcl.2025.130405_bb0220","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/mol.112.078964","article-title":"Methemoglobin formation by triapine,di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone(Dp44mT), and other anticancer thiosemicarbazones:identification of novel thiosemicarbazones and therapeutics that prevent this effect","volume":"82","author":"Quach","year":"2012","journal-title":"Mol Pharmacol"},{"issue":"40","key":"10.1016\/j.bmcl.2025.130405_bb0225","doi-asserted-by":"crossref","first-page":"42411","DOI":"10.18632\/oncotarget.6389","article-title":"Novel and potent anti-tumor and anti-metastatic di-2-pyridyl ketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents","volume":"6","author":"Sestak","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bmcl.2025.130405_bb0230","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","article-title":"Targeting ferroptosis as a vulnerability in cancer","volume":"22","author":"Lei","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmcl.2025.130405_bb0235","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41568-021-00417-2","article-title":"Connecting copper and cancer: from transition metal signalling to metalloplasia","volume":"22","author":"Ge","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmcl.2025.130405_bb0240","doi-asserted-by":"crossref","first-page":"6235","DOI":"10.1021\/ja109413c","article-title":"Copper binding agents acting as copper Ionophores Lead to caspase inhibition and Paraptotic cell death in human Cancer cells","volume":"133","author":"Tardito","year":"2011","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2025.130405_bb0245","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.freeradbiomed.2012.03.017","article-title":"The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells","volume":"52","author":"Nagai","year":"2012","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.bmcl.2025.130405_bb0250","doi-asserted-by":"crossref","DOI":"10.1002\/VIW.20230001","article-title":"Cell death mediateed by nanotechnology via the cuproptosis pathway: a novel horizon for cancer therapy","volume":"4","author":"Wei","year":"2023","journal-title":"View"},{"key":"10.1016\/j.bmcl.2025.130405_bb0255","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1021\/ja00905a001","article-title":"Hard and soft acids and bases","volume":"85","author":"Pearson","year":"1963","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2025.130405_bb0260","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1126\/science.151.3707.172","article-title":"Acids and bases","volume":"151","author":"Pearson","year":"1966","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2025.130405_bb0265","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejmech.2016.03.078","article-title":"Design, synthesis and biological evaluation of thiosemicarbazones, hydrazinobenzothiazoles and arylhydrazones as anticancer agents with a potential to overcome multidrug resistance","volume":"117","author":"Pape","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130405_bb0270","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jinorgbio.2010.07.012","article-title":"The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: an EPR study","volume":"104","author":"Jansson","year":"2010","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.bmcl.2025.130405_bb0275","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1021\/jm900552r","article-title":"Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors","volume":"52","author":"Yu","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130405_bb0280","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jinorgbio.2014.12.015","article-title":"Synthesis and characterization of the anticancer and metal binding properties of novel pyrimidinylhydrazone derivatives","volume":"144","author":"Pape","year":"2015","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.bmcl.2025.130405_bb0285","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10534-015-9905-1","article-title":"Improved cytotoxicity of pyridyl-substituted thiosemicarbazones against MCF-7 when used as metal ionophores","volume":"29","author":"Akladios","year":"2016","journal-title":"Biometals"},{"key":"10.1016\/j.bmcl.2025.130405_bb0290","series-title":"Encyclopedia of Molecular Pharmacology","article-title":"Antimetabolites","author":"Konstantinov","year":"2008"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130405_bb0295","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2174\/1573406415666190430143535","article-title":"Anti-mycobacterial peroxides: a new class of agents for development against tuberculosis","volume":"16","author":"van der Westhuyzen","year":"2020","journal-title":"Med Chem"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130405_bb0300","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2174\/156720110791560991","article-title":"Iron chelators: development of novel compounds with high and selective anti-tumour activity","volume":"7","author":"Kovacevic","year":"2010","journal-title":"Current Drug Disc"},{"key":"10.1016\/j.bmcl.2025.130405_bb0305","doi-asserted-by":"crossref","DOI":"10.1002\/14356007.a07_567.pub2","article-title":"Copper compounds","volume":"1\u201331","author":"Zhang","year":"2016","journal-title":"Ullmann\u2019s Encyclopedia of Industrial Chemistry"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130405_bb0310","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.gca.2005.10.018","article-title":"Kinetics of Fe(III) precipitation in aqueous solutions at pH 6.0\u20139.5 and 25\u00b0C","volume":"70","author":"Pham","year":"2006","journal-title":"Geochim Cosmochim Acta"},{"issue":"12","key":"10.1016\/j.bmcl.2025.130405_bb0315","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1167\/iovs.10-5410","article-title":"Intralysosomal iron induces lysosomal membrane permeabilization and cathepsin D-mediated cell death in trabecular meshwork cells exposed to oxidative stress","volume":"51","author":"Lin","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25003142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25003142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T08:15:12Z","timestamp":1761639312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25003142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":62,"alternative-id":["S0960894X25003142"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130405","relation":{},"ISSN":["0960-894X"],"issn-type":[{"type":"print","value":"0960-894X"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Pyrimidinyl Hydrazones: Selective for anti-Cancer cytotoxicity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130405","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"130405"}}